Data Sheet 1_Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanc

70 patients with resectable locally advanced esophageal squamous cell carcinoma were enrolled in a randomized, controlled, open-label, phase 2 trial from July 2019 to June 2023. The trial compared sequential versus concurrent administration of paclitaxel/cisplatin chemotherapy with the PD-1 inhibitor toripalimab, measuring pathological complete remission, adverse events, and survival outcomes. Yan Zheng published the results under a CC-BY-4.0 license.

Use Cases

• Compare pathological complete remission rates based on treatment administration sequence.
• Analyze the incidence and severity of treatment-related adverse events between sequential and concurrent groups.
• Model survival outcomes (OS/DFS) for patients receiving neoadjuvant immunochemotherapy.
• Investigate correlations between specific adverse events (nausea, diarrhea) and concurrent drug administration.
• Benchmark safety profiles of neoadjuvant regimens involving PD-1 inhibitors.

Strengths

• Data originates from a prospective, randomized controlled trial, providing a structured experimental design.
• Includes detailed outcomes for 70 enrolled patients and 54 who underwent surgery.
• Reports specific metrics like a 22.2% overall pCR rate and a 14.2% incidence of grade 3–5 TRAEs.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small (393.6 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

Data collected from a randomized, controlled, open-label, phase 2 clinical trial.

Time Range

July 2019 to June 2023

Freshness

Last updated 2026-05-07 04:37:15; freshness should be verified.